With a growing range of new vaccines coming on to the market and evidence that some countries simply could not sustain the significant increases in funding required to maintain immunisation programmes, Gavi's first-ever strategy incorporated a detailed review of how best to deploy its growing resources:

STRATEGIC GOALS

Four strategic goals underpinned Phase II

Strategic Goal 1

Contribute to the strengthening the capacity of the health system to deliver immunisation and other health services in a sustainable manner

Contribute to the strengthening the capacity of the health system to deliver immunisation and other health services in a sustainable manner

Strategic Goal 2

Accelerate the uptake and use of underused and new vaccines and associated technologies and improve vaccine supply security

Accelerate the uptake and use of underused and new vaccines and associated technologies and improve vaccine supply security

Strategic Goal 3

Increase the predictability and sustainability of long-term financing for national immunisation programmes

Increase the predictability and sustainability of long-term financing for national immunisation programmes

Strategic Goal 4 

Increase and assess the added value of Gavi as a public-private global health partnership through improved efficiency, increased advocacy and continued innovation

Increase and assess the added value of Gavi as a public-private global health partnership through improved efficiency, increased advocacy and continued innovation

WORKPLAN, ACTIVITIES, OUTPUTS

With a total budget of US$ 297 million available for the strategy's four-year life cycle, any given year in the Gavi strategy contained up to 100 activities. To help measure progress, these activities are reported against 17 outputs.

The 2010 Work Plan Report highlights the 2010 progress under each output. It is based on the reporting provided by WHO, UNICEF, World Bank, AVI TAC and the Gavi Secretariat. The paper includes an annex table summarising the progress per output against the 2010 work plan targets.

Related downloads

Latest news

Geneva, 28 October 2020 – Gavi, the Vaccine Alliance announced today that it had signed a Statement of Intent with Sanofi and GSK to provide 200 million doses of the companies’ adjuvanted recombinant protein COVID-19 vaccine to the COVAX Facility…

Around 450,000 girls aged 9-10 will receive the human papillomavirus (HPV) vaccine, which protects against the leading cause of cervical cancer. Myanmar currently has the second-highest incidence of cervical cancer in Southeast Asia.

Japanese Government pledges US$ 130 million in funding to the Gavi COVAX Advance Market Commitment (AMC), bringing the total raised to roughly US$ 1.8 billion.

Last updated: 14 Jan 2020

Subscribe to our newsletter